This prospective study of 400 patients assessed whether surveillance aids detection of early-stage pancreatic ductal adenocarcinoma or precursor lesions (PRLs) and improves prognosis. Based on the findings, the authors concluded that surveillance of CDNK2A mutation carriers is relatively successful, but the benefit of surveillance in families with familial pancreatic cancer is less evident.
The Centers for Medicare & Medicaid Services (CMS) released a proposal to reduce the Average Sales Price reimbursement rate based on primary care service areas, sparking concerns over its singular focus on drug costs. ASCO responded strongly in opposition, and will keep pressure on CMS to withdraw the proposal and focus on real reform. Individuals may voice opposition through ASCO’s ACT Network.
CancerLinQ LLC has completed agreements with 36 oncology practices from around the country to begin implementing CancerLinQ™, the groundbreaking health information technology (HIT) platform that will harness big data analytics to help oncologists rapidly improve high-quality care to patients with cancer.
Best of ASCO® Chicago will feature the most significant research and educational highlights from the ASCO Annual Meeting, and bring together expert faculty to discuss and place in to clinical context the top abstracts in select disease sites. Can’t make it to Chicago? Best of ASCO Meetings are also being held this summer in Washington, DC (July 15-16), and San Diego (August 12-13).
Visit the redesigned iPlanner to browse abstract titles, search sessions, and build your personalized schedule. Improvements to the tool include a simplified program and enhanced search. The iPlanner website automatically syncs with the iPlanner mobile app for seamless planning.